Epicrispr Biotechnologies has secured $68 million in Series B financing to support the clinical development of its disease-modifying therapy EPI-321. The financing was led by Ally Bridge Group with participation from SOLVE FSHD.
PRIVATEMar 27, 2025
Amount Raised
$68 Million
Round Type
Series B
San FranciscoBiotechnologyHealth CareGeneticsTherapeutics
Investors
Solve FshdAlly Bridge Group
Description
Epicrispr Biotechnologies, a biotechnology company focused on developing curative therapies, has announced it secured $68 million in the first close of its Series B financing. The proceeds will be used for the clinical development of EPI-321, aiming to treat facioscapulohumeral muscular dystrophy (FSHD). The Series B was led by Ally Bridge Group, with participation from SOLVE FSHD and other investors. The clinical trial is expected to begin in 2025 in New Zealand.
Company Information
Company
Epicrispr Biotechnologies
Location
San Francisco, California, United States
About
Epicrispr Biotechnologies is a biotechnology company focused on developing curative therapies for genetic neuromuscular diseases. Their lead program, EPI-321, is a first-in-class disease-modifying therapy for facioscapulohumeral muscular dystrophy (FSHD). The company aims to advance innovative treatments that address the underlying causes of genetic disorders. With recent funding, Epicrispr is entering the clinical stage to bring much-needed therapies to patients.
Fundz sees it the moment Epicrispr Biotechnologies raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
San FranciscoBiotechnologyHealth CareGeneticsTherapeutics